Endothelin-1 concentrations in pericardial fluid are more elevated in patients with ischemic heart disease than in patients with nonischemic heart disease

Japanese Heart Journal

Volumn 44, Issue 5, 2003, Pages 633-644

  Namiki, Atsuhi ^a   Kubota, Tetsuya ^a   Fukazawa, Masayuki ^a   Ishikawa, Michiro ^a   Moroi, Masao ^a   Aikawa, Jo ^a   Ebine, Kunio ^a   Yamaguchi, Tetsu ^a  

^a TOHO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Endothelin 1; Ischemic heart disease; Nonischemic heart disease; Pericardial fluid

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITRATE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG RESPONSE; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; FEMALE; HEART DISEASE; HEART FAILURE; HEART MUSCLE; HUMAN; ISCHEMIC HEART DISEASE; MALE; PATHOPHYSIOLOGY; PERICARDIAL EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN-1; GROWTH SUBSTANCES; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PERICARDIAL EFFUSION; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 27244433287     PISSN: 00214868     EISSN: 1348673X     Source Type: Journal    
DOI: 10.1536/jhj.44.633     Document Type: Article

References (44)

1. Vigna C, Russo A, De Rito V, et al. Regional wall motion analysis by dobutamine stress echocardiography to distinguish between ischemic and nonischemic dilated cardiomyopathy. Am Heart J 1996; 131: 537-43.
2. Budoff MJ, Shavelle DM, Lamont DH, et al. Usefulness of electron beam computed tomography scanning for distinguishing ischemic from nonischemic cardiomyopathy. J Am Coll Cardiol 1998; 32: 1173-8.
3. Bart BA, Shaw LK, McCants CB, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol 1997; 30: 1002-8.
4. Follath F, Cleland JGF, Klein W, Murphy R. Etiology and response to drug treatment in heart failure. J Am Coll Cardiol 1998; 32: 1167-72.
5. Follath F. Nonischemic heart failure: epidemiology, pathophysiology and progression of disease. J Cardiovasc Pharmacol 1999; 33: S31-5.
6. Serneri GGN, Boddi M, Cecioni I, et al. Cardiac angiotensin II formation in the clinical course of heart failure and its relationship with left ventricular function. Circ Res 2001; 88: 961-8.
7. Fukuchi M, Giaid A. Expression of endothelin-1 and endothelin-converting enzyme-1 mRNAs and proteins in failing human hearts. J Cardiovasc Pharmacol 1998; 31: S421-3.
8. Francis SE, Holden H, Holt CM, Duff GW. Interleukin-1 in myocardium and coronary arteries of patients with dilated cardiomyopathy. J Mol Cell Cardiol 1998; 30: 215-23.
9. Gwechenberger M, Mendoza LH, Youker KA, et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. Circulation 1999; 99: 546-51.
10. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor- α and tumor necrosis factor receptors in the failing human heart. Circulation 1996; 93: 704-11.
11. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation 1995; 92: 1487-93.
12. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000; 342: 1077-84.
13. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. N Engl J Med 1986; 314: 1547-52.
14. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325: 1468-75.
15. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6.
16. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure: the Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994; 90: 1765-73.
17. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996; 334: 1349-55.
18. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14.
19. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
20. Gheorghiade M, Young JB, Uretsky BF, Packer M. The effects of digoxin withdrawal in patients with stable heart failure due to coronary artery disease compared to primary cardiomyopathy; insights from the PROVED and RADIANCE studies. Circulation 1995; 92: I-142.
21. CIBIS-II Investigators and Committees. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353: 9-13.
22. Abraham WT, Singh B. Ischemic and nonischemic heart failure do not require different treatment strategies. J Cardiovasc Pharmacol 1999; 33: S1-7.
23. Williams JF Jr, Bristow MR, Fowler MB, et al. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines (Committee on evaluation and management of heart failure). Circulation 1995; 92: 2764-84.
24. Rauchhaus M, Doehner W, Francis DP, et al. Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000; 102: 3060-7.
25. Miyauchi T, Yanagisawa M, Tomizawa T, et al. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 1989; 2: 53-4.
26. Hiroe M, Hirata Y, Fujita N, et al. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am J Cardiol 1991; 68: 1114-5.
27. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992; 85: 510-7.
28. McMurray JJ, Ray SG, Abdullah I, Dargie HJ, Morton JJ. Plasma endothelin in chronic heart failure. Circulation 1992; 85: 1374-9.
29. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85: 504-9.
30. Wei CM, Lerman A, Rodeheffer RJ, et al. Endothelin in human congestive heart failure. Circulation 1994; 89: 1580-6.
31. Zolk O, Quattek J, Sitzler G, et al. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure. Circulation 1999; 99: 2118-23.
32. Tonnessen T, Giaid A, Saleh D, Naess PA, Yanagisawa M, Christensen G. Increased in vivo expression and production of endothelin-1 by porcine cardiomyocytes subjected to ischemia. Circ Res 1995; 76: 767-72.
33. Serneri GGN, Cecioni I, Vanni S, et al. Selective upregulation of cardiac endothelin system in patients with ischemic but not idiopathic dilated cardiomyopathy: endothelin-1 system in the human failing heart. Circ Res 2000; 86: 377-85.
34. Ito H, Adachi S, Tamamori M, et al. Mild hypoxia induces hypertrophy of cultured neonatal rat cardiomyocytes: a possible endogenous endothelin-1-mediated mechanism. J Mol Cell Cardiol 1996; 28: 1271-7.
35. Gibson AT, Segal MB. A study of the composition of pericardial fluid, with special reference to the probable mechanism of fluid formation. J Physiol (London) 1978; 277: 367-77.
36. Fujita M, Ikemoto M, Kishishita M, et al. Elevated basic fibroblast growth factor in pericardial fluid of patients with unstable angina. Circulation 1996; 94: 610-3.
37. Corda S, Mebazaa A, Gandolfini MP, et al. Trophic effect of human pericardial fluid on adult cardiac myocytes. Circ Res 1997; 81: 679-87.
38. Miyazaki T, Pride HP, Zipes DP. Prostaglandins in the pericardial fluid modulate neural regulation of cardiac electrophysiological properties. Circ Res 1990; 66: 163-75.
39. Yoneda T, Fujita M, Kihara Y, et al. Pericardial fluid from patients with ischemic heart disease accelerates the growth of human vascular smooth muscle cells. Jpn Circ J 2000; 64: 495-8.
40. Uchida Y, Yanagisawa-Miwa A, Nakamura F, et al. Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: an experimental study. Am Heart J 1995; 130: 1182-8.
41. Szokodi I, Horkay F, Kiss P, et al. Characterization of canine pericardial fluid endothelin-1 levels. J Cardiovasc Pharmacol 1998; 31: S399-400.
42. Mebazaa A, Wetzel RC, Dodd-o JM, et al. Potential paracrine role of the pericardium in the regulation of cardiac function. Cardiovasc Res 1998; 40: 332-42.
43. Horkay F, Szokodi I, Selmeci L, et al. Presence of immunoreactive endothelin-1 and atrial natriuretic peptide in human pericardial fluid. Life Sci 1998; 62: 267-74.
44. Szokodi I, Horkay F, Merkely B, et al. Intrapericardial infusion of endothelin-1 induces ventricular arrhythmias in dogs. Cardiovasc Res 1998; 38: 356-64.